CLCZ696G2301 (PARADISE-MI)

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CLCZ696G2301 (PARADISE-MI), covering 2021-11-26 to 2021-11-26. Get the full timeline:

Most recent: Clinical Trial Update: Open-label Extension Study for CLCZ696G2301 (PARADISE-MI) [Phase 3]